LMAT

LeMaitre Vascular, Inc. Healthcare - Medical Instruments & Supplies Investor Relations →

NO
27.5% ABOVE
↑ Moving away Was 25.1% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $73.71
14-Week RSI 31
Rel. Volume (14w) This week's trading vs. the 14-week average 1.6x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 0.98

LeMaitre Vascular, Inc. (LMAT) closed at $93.95 as of 2026-06-19, trading 27.5% above its 200-week moving average of $73.71. The stock moved further from the line this week, up from 25.1% last week. The 14-week RSI sits at 31, indicating neutral momentum.

Trading volume is running at 1.6x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.98 ratio) is neutral — neither side is clearly dominating.

Over the past 978 weeks of data, LMAT has crossed below its 200-week moving average 4 times. On average, these episodes lasted 34 weeks. Historically, investors who bought LMAT at the start of these episodes saw an average one-year return of +33.2%.

With a market cap of $2.1 billion, LMAT is a mid-cap stock. The company generates a free cash flow yield of 2.5%. Return on equity stands at 16.5%, a solid level. The stock trades at 5.3x book value.

Share count has increased 3.1% over three years, indicating dilution. LMAT passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.

Over the past 18.8 years, a hypothetical investment of $100 in LMAT would have grown to $1494, compared to $694 for the S&P 500. That represents an annualized return of 15.4% vs 10.8% for the index — confirming LMAT as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

Free cash flow has been growing at a 49.8% compound annual rate, with 4 consecutive years of positive cash generation.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: LMAT vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After LMAT Crosses Below the Line?

Across 4 historical episodes, buying LMAT when it crossed below its 200-week moving average produced an average return of +30.0% after 12 months (median +59.0%), compared to +10.2% for the S&P 500 over the same periods. 75% of those episodes were profitable after one year. After 24 months, the average return was +42.5% vs +28.2% for the index.

Each line shows $100 invested at the moment LMAT crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices LMAT would reach each dislocation threshold.

Current Bean Score +1.59σ
Current FCF Yield 3.67%
Baseline Yield 3.20%
Historical σ 0.50pp

Dislocation Price Levels

Prices where LMAT's Bean Score would hit each σ threshold. Valid until next earnings report (date TBD — last report: 2026-03-31).

LevelσPriceSignal
Deep Value+2σ$89.48Unusually cheap — potential buy zone
Value+1σ$102.90Cheap vs. own history
Fair Value+0σ$121.06Historical mean behavior
Expensive-1σ$146.99Expensive vs. own history
Deep Expensive-2σ$187.07Unusually expensive — potential trim zone

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Data depth: 2 quarterly baselines, 22 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

11 / 13 weeks minimum

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from LMAT's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

Yield Dislocation +0.11σ Dividend yield vs own 10-yr norm
Drawdown Score +0.16σ Distance from line vs own history
Sector-Relative -1.56σ Vs sector median this week
Buyback Acceleration -0.0pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History -0.1pp Vs own recent annual mean
Earnings Quality Improving Accrual gap trend (-7.6pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Advertisement

Historical Touches

LMAT has crossed below its 200-week MA 4 times with an average 1-year return of +33.2% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Dec 2007Nov 200910062.0%-63.7%+1777.0%
Mar 2010Apr 201022.4%+52.9%+2425.2%
Dec 2018Feb 201984.4%+61.0%+354.6%
Feb 2020Aug 20202625.6%+82.6%+251.5%
Average34+33.2%

Frequently Asked Questions

Is LMAT below its 200-week moving average?

No. LeMaitre Vascular, Inc. (LMAT) is currently 27.5% above its 200-week moving average of $73.71. It would need to fall to $73.71 to cross below the line.

What is LMAT's 200-week moving average price?

LeMaitre Vascular, Inc.'s 200-week moving average is $73.71 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when LMAT drops below its 200-week moving average?

LMAT has crossed below its 200-week moving average 4 times in our data. On average, buying at that moment produced a one-year return of +33.2%. These dips have historically been decent entry points. These episodes lasted 34 weeks on average.

Is LMAT a good value right now?

Here's what our data says about LMAT as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 31. Free cash flow yield is 2.5%. Return on equity is 16.5%. Price-to-book is 5.3x. This is not a buy or sell recommendation — always do your own research.

How does LMAT compare to the S&P 500?

Over the past 18.8 years, $100 invested in LMAT would have grown to $1494, compared to $694 for the S&P 500. That's 15.4% annualized vs 10.8% for the index. LMAT has outperformed the broader market over this period.

Does LMAT pay a dividend?

Yes. LeMaitre Vascular, Inc. currently pays a dividend yield of 107.00%.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-06-19